Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 100 entries
View as:

GEM05 for Patients With Multiple Myeloma More Than 65 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT00443235 Org: User:
Start: 03/31/05 End: 12/31/09 Due: 12/31/10

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Phase: N/A Priority: Normal
NCT ID: NCT01491763 Org: User:
Start: 01/31/08 End: 12/31/22 Due: 12/31/23

Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS

Phase: N/A Priority: Normal
NCT ID: NCT01540812 Org: User:
Start: 02/29/12 End: 12/01/19 Due: 12/01/20

Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01435343 Org: User:
Start: 07/31/12 End: 12/31/16 Due: 12/31/17

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02036489 Org: User:
Start: 01/31/08 End: 12/01/19 Due: 12/01/20

TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant

Phase: N/A Priority: Normal
NCT ID: NCT00386412 Org: User:
Start: 11/30/05 End: 09/30/09 Due: 09/30/10

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Phase: N/A Priority: Normal
NCT ID: NCT02636010 Org: User:
Start: 06/30/16 End: 02/20/20 Due: 02/20/21

GEM-CLARIDEX: Ld vs BiRd

Phase: N/A Priority: Normal
NCT ID: NCT02575144 Org: User:
Start: 09/30/15 End: 10/31/24 Due: 10/31/25

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT04107727 Org: User:
Start: 09/05/19 End: 09/30/24 Due: 09/30/25

Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01376401 Org: User:
Start: 07/31/11 End: 12/31/15 Due: 12/31/16

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Phase: N/A Priority: Normal
NCT ID: NCT00390897 Org: User:
Start: 07/31/03 End: 12/31/07 Due: 12/31/08

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Phase: N/A Priority: Normal
NCT ID: NCT05527340 Org: User:
Start: 09/30/22 End: 12/31/29 Due: 12/31/30

Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection

Phase: N/A Priority: Normal
NCT ID: NCT00388167 Org: User:
Start: 03/31/04 End: 02/29/08 Due: 02/28/09

Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)

Phase: N/A Priority: Normal
NCT ID: NCT00504764 Org: User:
Start: 07/31/07 End: 10/31/14 Due: 10/31/15

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Phase: N/A Priority: Normal
NCT ID: NCT03280160 Org: User:
Start: 09/07/17 End: 09/30/22 Due: 09/30/23

A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF

Phase: N/A Priority: Normal
NCT ID: NCT00765050 Org: User:
Start: 01/31/09 End: 10/31/12 Due: 10/31/13

Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

Phase: N/A Priority: Normal
NCT ID: NCT03661515 Org: User:
Start: 07/17/18 End: 10/15/19 Due: 10/15/20

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Phase: N/A Priority: Normal
NCT ID: NCT01358201 Org: User:
Start: 05/31/10 End: 12/31/22 Due: 12/31/23

Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00488436 Org: User:
Start: 05/31/02 End: 12/31/07 Due: 12/31/08

MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning

Phase: N/A Priority: Normal
NCT ID: NCT00564200 Org: User:
Start: 11/30/07 End: 10/31/14 Due: 10/31/15

Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT00840346 Org: User:
Start: 09/30/09 End: 12/31/18 Due: 12/31/19

Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.

Phase: N/A Priority: Normal
NCT ID: NCT03311815 Org: User:
Start: 10/06/17 End: 10/15/19 Due: 10/15/20

Antifungal Use in Oncohematological Neutropenic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00386802 Org: User:
Start: 08/31/06 End: 01/31/09 Due: 01/31/10

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT01041040 Org: User:
Start: 10/31/07 End: 01/31/13 Due: 01/31/14

Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)

Phase: N/A Priority: Normal
NCT ID: NCT00465933 Org: User:
Start: 03/31/99 End: 11/30/07 Due: 11/30/08